Advancing countermeasures against 21st century health threats by bringing together public private partnerships and advancing innovation. Part of HHS/ASPR.
Joined April 2017
- Tweets 3,057
- Following 214
- Followers 9,781
- Likes 324
2,014 Photos and videos
Building domestic manufacturing capacity, BARDA and Schott inaugurated a new production line for production of pharmaceutical glass vials at their facility in Lebanon, PA. Thanks to a longstanding partnership between @BARDA and Schott Pharma, the new production lines, once complete, will be used to make up to 140 million additional 2R vials annually and will support rapid scale production and delivery of medical countermeasures during emergencies.
2
2
430
We awarded a Project BioShield contract to @AVITAMedical for RECELL, an FDA-approved autograft-sparing device that uses a small sample of a patient’s own skin to treat full-thickness burns & trauma, enhancing readiness for radiological & nuclear incidents: ow.ly/AA7Z50Z9mT2
1
420
This #BARDAInnovation Spotlight highlights the Quic Liver Kidney test being developed by @in_Diagnostics. Their test pairs with a smartphone app to assess organ health at home, enabling decentralized monitoring during both daily care and emergencies. 🔗: drive.hhs.gov/map/index.html
2
2
4
325
BARDA awarded a new Project BioShield contract to @ShionogiUS to enhance nat'l preparedness for biothreats and multidrug-resistant infections while expanding manufacturing to domestic facilities to build stronger defenses against future health emergencies: ow.ly/Uz1550YRbL1
1
1
3
582
This rapid diagnostic can help determine if a patient’s acute respiratory infection is caused by a bacterial infection. It can also help inform treatment decisions and reduce unnecessary antibiotic use, which has the potential to improve #AntibioticStewardship. ⬇️
1
1
267
This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to combat antimicrobial resistance (#AMR). Learn more: medicalcountermeasures.gov/b…
1
208
BARDA's FASTx solicitation is back! We're funding #PlatformTechnologies that leverage #antiviral conjugates to develop therapeutics against filoviruses and other emerging threats. Learn more here: ow.ly/qv1u50YO4k0
3
757
We're advancing an AI-enabled assay from Ad Astra Diagnostics that produces results from a blood sample in less than 3 minutes. QScout CBC is designed to provide meaningful results to frontline providers in ambulances, urgent care centers, clinics & more: ow.ly/ugSS50YFbk1
1
3
906
We’re accepting proposals for a partner to lead the BARDA Accelerator Network Diagnostics and Medical Devices Hub! Submissions are due by 12PM ET on April 20, 2026. Learn more: ow.ly/74H550YEwG1
2
7
1,267
Today, there are no @US_FDA-approved broad-spectrum therapeutics to treat people with dengue, Zika, West Nile, and Chikungunya and other diseases caused by members of these viral families – but we’re working to change that. BARDA and VITAL, a BARDA Accelerator Network Hub, are partnering to offer prizes to the innovators who can develop novel broad-spectrum antiviral drugs that address this gap in the antiviral pipeline. aspr.hhs.gov/newsroom/Pages/…
ALT A person in a lab coat looks through a microscope. The text reads: "SMART - New Prize Competition to Advance Novel Antiviral Therapies for Dengue, Zika, West Nile, Chikungunya, and Related Viruses." A red button below says, "Link In Post." ASPR logo is at the bottom.
3
2
6
916
Together with @CompMedUCLA, we're furthering development of the SwabSeq Metagenomic Diagnostic Platform, designed to detect viral pathogens. It could serve as a rapid response tool to detect a novel respiratory virus in a #HealthSecurity emergency: medicalcountermeasures.gov/b…
1
4
484
We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral…
1
1
2
513
BARDA is bolstering national preparedness through the procurement of multiple #MedicalCountermeasures needed to protect the U.S. population from chemical, biological, radiological, and nuclear (#CBRN) threats.
3
1
6
2,493
Procuring #MedicalCountermeasures that are FDA-approved, licensed, and cleared can help ensure their availability in future health security emergencies. See more in our #CBRN portfolio here: medicalcountermeasures.gov/b…
350
We’re partnering with @FluGenInc and @OsivaxVaccines to develop innovative #influenza vaccines, which could be used to address both pandemic and seasonal flu. If successful, these vaccines could help bolster national pandemic preparedness efforts.
6
3
379
Current flu vaccines, while effective, may not address all variants that could emerge during an influenza pandemic. Therefore, broad-acting vaccines like these could protect against multiple strains and help bolster pandemic preparedness: medicalcountermeasures.gov/b…
225
@OsivaxVaccines is developing OVX836, a next-generation, broad-spectrum vaccine. It is designed to provide long-lasting protection against both seasonal and pandemic #influenza A strains, allowing for a universal approach to vaccination during a flu pandemic.
126
@FluGenInc is developing a novel, live-attenuated vaccine candidate that is administered intranasally. This effort could help identify Correlates of Protection biomarkers that may streamline the development pathway for further research and development.
130